XBIT News and Press, XBiotech Inc. From 12/17/19

AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019. T...

Shares of XBiotech (NASDAQ: XBIT) more than doubled today after the tiny company agreed to sell its lead drug candidate, bermekimab, to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen for $750 million up front and up to $600 million in potential milestone payments. XBiotech will als...

Gainers: Synthorx (NASDAQ: THOR )  +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...

Synthorx (NASDAQ: THOR ) +169%  on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...

XBiotech (NASDAQ: XBIT ) inks an agreement with Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab. More news on: XBiotech Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, Read more ...

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today...

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical study eva...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...

AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis (AD) (a...

Enrollment is underway in a Phase 2 clinical trial evaluating XBiotech's ( XBIT -0.3% ) bermekimab in patients with hidradenitis suppurativa, a condition characterized by small painful lumps under the skin, typically in area where skin rubs together (e.g., armpits, groin, buttocks, br...